- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Granules India net profit up 34 percent to Rs 111.4 crore in Q1
"This is the result of operational excellence and a vigilant watch over our margins through optimization of the product mix and by increased capacities and optimal capacity utilisation," Granules India Chairman and MD Krishna Prasad Chigurupati said.
New Delhi: Drug firm Granules India on Friday reported a 33.87 percent rise in its consolidated net profit to Rs 111.44 crore for the quarter ended June 30, 2020, mainly on account of robust sales.
The company had posted a net profit of Rs 83.24 crore for the corresponding period of the previous financial year, Granules India said in a filing to the BSE.
Its consolidated revenue from operations stood at Rs 735.59 crore for the quarter under consideration. It was Rs 595.27 crore for the same period a year ago, it added.
"This is the result of operational excellence and a vigilant watch over our margins through optimization of the product mix and by increased capacities and optimal capacity utilisation," Granules India Chairman and MD Krishna Prasad Chigurupati said.
The company also declared its first interim dividend of 25 paise per share of face value of Re 1 each representing 25 percent of paid-up capital for the financial year 2020-21, Granules India said.
Shares of Granules India Ltd were trading at Rs 253.90 per scrip on the BSE, up 3.23 percent from its previous close.
Read also: Granules Pharma recalls Metformin Hydrochloride Tablets in US over excessive NDMA level
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751